Taiga Biotechnologies
Biotechnology, E. Montview Blvd., Aurora, , 80045, Colorado, 12635, United States, 11-50 Employees
Phone Number: 72********
Who is TAIGA BIOTECHNOLOGIES
Taiga Biotechnologies, Inc. is a clinical stage biotechnology company focused on harnessing the power of the immune system to fight solid tumors and infectious disease and on improving bl...
Read More
- Headquarters: 12635 E. Montview Blvd., Aurora, Colorado, 80045, United States
- Date Founded: 2006
- Employees: 11-50
- Revenue: $1 Million to $5 Million
- Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836 | NAICS Code: 541714 | Show More
Does something look wrong? Fix it. | View contact records from TAIGA BIOTECHNOLOGIES
Taiga Biotechnologies Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Taiga Biotechnologies
Answer: Taiga Biotechnologies's headquarters are located at E. Montview Blvd., Aurora, , 80045, Colorado, 12635, United States
Answer: Taiga Biotechnologies's phone number is 72********
Answer: Taiga Biotechnologies's official website is https://taigabiotech.com
Answer: Taiga Biotechnologies's revenue is $1 Million to $5 Million
Answer: Taiga Biotechnologies's SIC: 2836
Answer: Taiga Biotechnologies's NAICS: 541714
Answer: Taiga Biotechnologies has 11-50 employees
Answer: Taiga Biotechnologies is in Biotechnology
Answer: Taiga Biotechnologies contact info: Phone number: 72******** Website: https://taigabiotech.com
Answer: Taiga Biotechnologies, Inc. is a clinical stage biotechnology company focused on harnessing the power of the immune system to fight solid tumors and infectious disease and on improving blood stem cell transplantation. What we do: For healthy immune systems, our immunotherapy programs temporarily boost the immune system so that it functions better to fight both solid tumors and infectious disease. For compromised immune systems, our regenerative medicine program generates a new, healthy immune system. 1. Our lead Cell-Based Immunotherapy product candidate, TBX-3400, uses a patients own immune cells to help fight against solid tumors and infectious disease. TBX-3400 is an autologous cell product made from peripheral blood mononuclear cells that are treated ex vivo with our fusion protein and then delivered intravenously back to the patient the following day. Our Cell-Based Immunotherapy technology has several advantages over current immunotherapy approaches. We do not need to expand T-cells in the laboratory to generate enough T-cells for treatment. We do not limit the response to the tumor based by engineering the specificity of the T-cell. We do not require genetic modification of the T-cells to enable antitumor activity. 2. Our Bone Marrow Engraftment Enhancer (BMEE) program is developing a first-line product, TBX-2400, to enhance the engraftment of hematopoietic stem and progenitor cells during an allogeneic hematopoietic stem cell transplant (HSCT). Our BMEE goal is to increase the chance of long-term survival of a HSCT recipient by: increasing the probability of a successful engraftment; increasing the rate of reconstitution of mature and functional lymphocytes; and managing the complications associated with HSCT.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month